Replimune Group (id:7803 REPL)
14.93 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 9:43:30 AM)
Exchange closed, opens in 23 hours 46 minutes
About Replimune Group
Market Capitalization 1.02B
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
| Headquarters (address) |
500 Unicorn Park Drive Woburn 01801 MA United States |
| Phone | 781 222 9600 |
| Website | https://www.replimune.com |
| Employees | 331 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | REPL |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 4.92 - 17.00 |
| Market Capitalization | 1.02B |
| P/E trailing | -4.61 |
| P/E forward | -5.55 |
| Price/Book | 2.68 |
| Beta | 1.19 |
| EPS | -3.04 |
| EPS United States (ID:6, base:3402) | 24.22 |